Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Bexsero Antibody Persistence and Booster Response
NCT01139021Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease (6 arms), sponsored by Novartis. Primary endpoints: Geometric Mean Titers to Assess Antibody Persistence, Percentage of Subjects With hSBA >= 1:5 and hSBA >= 1:8 and 1 more. Started Jun 2010; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01139021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01139021.